Do analysts rate ACB or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ACB or APLM?

Apollomics has lower revenue, but higher earnings than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis $247.82M 0.66 -$88.13M -$1.56 N/A Apollomics $8.50M 4.80 -$10.94M N/A N/A

Do analysts recommend APLM or ORMP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, APLM or ORMP?

Oramed Pharmaceuticals has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.80 -$10.94M N/A N/A Oramed Pharmaceuticals N/A N/A $64.05M $2.59 1.56

Is APLM or ORMP more profitable?

Apollomics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Oramed Pharmaceuticals N/A -5.37% -4.83%

Do analysts rate APLM or MOLN?

Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 113.10%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings and valuation, APLM or MOLN?

Apollomics has higher revenue and earnings than Molecular Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.80 -$10.94M N/A N/A Molecular Partners N/A N/A -$74.41M -$1.94 N/A

Is APLM or MOLN more profitable?

Apollomics' return on equity of 0.00% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Molecular Partners N/A -66.62% -54.85%

Do analysts prefer APLM or NRXP?

NRx Pharmaceuticals has a consensus price target of $38.25, indicating a potential upside of 920.00%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, APLM or NRXP?

Apollomics has higher revenue and earnings than NRx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.80 -$10.94M N/A N/A NRx Pharmaceuticals $2.29M 59.25 -$28.62M -$1.09 N/A

Is APLM or NRXP more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A NRx Pharmaceuticals N/A N/A -202.92%

Do analysts recommend APLM or MIST?

Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 525.00%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher earnings & valuation, APLM or MIST?

Apollomics has higher revenue and earnings than Milestone Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.80 -$10.94M N/A N/A Milestone Pharmaceuticals $1.78M 80.95 -$63.06M -$0.68 N/A

Is APLM or MIST more profitable?

Apollomics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Milestone Pharmaceuticals N/A -339.33% -61.79%

Apollomics (APLM) Competitors

$18.58 -0.28 (-1.46%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$18.58 0.00 (0.00%)

As of 07/24/2026 04:10 PM Eastern

Compare

APLM vs. ACB, ORMP, MOLN, NRXP, and MIST

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include Aurora Cannabis (ACB), Oramed Pharmaceuticals (ORMP), Molecular Partners (MOLN), NRx Pharmaceuticals (NRXP), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Apollomics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Apollomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
Apollomics	N/A	N/A	N/A

Aurora Cannabis has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has lower revenue, but higher earnings than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	0.66	-$88.13M	-$1.56	N/A
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A

In the previous week, Aurora Cannabis had 5 more articles in the media than Apollomics. MarketBeat recorded 6 mentions for Aurora Cannabis and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Aurora Cannabis' score of 0.53 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Positive
Apollomics	Very Positive

Summary

Aurora Cannabis beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Oramed Pharmaceuticals?

Apollomics (NASDAQ:APLM) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat Apollomics' score of 1.87 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Very Positive
Oramed Pharmaceuticals	Very Positive

Apollomics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Oramed Pharmaceuticals has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56

Summary

Apollomics beats Oramed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Apollomics compare to Molecular Partners?

Apollomics (NASDAQ:APLM) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Apollomics' return on equity of 0.00% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Molecular Partners	N/A	-66.62%	-54.85%

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 113.10%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.87 equaled Molecular Partners'average media sentiment score.

Company	Overall Sentiment
Apollomics	Very Positive
Molecular Partners	Very Positive

Apollomics has higher revenue and earnings than Molecular Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A
Molecular Partners	N/A	N/A	-$74.41M	-$1.94	N/A

Apollomics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Apollomics and Molecular Partners tied by winning 5 of the 10 factors compared between the two stocks.

How does Apollomics compare to NRx Pharmaceuticals?

Apollomics (NASDAQ:APLM) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

NRx Pharmaceuticals has a consensus price target of $38.25, indicating a potential upside of 920.00%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-202.92%

Apollomics has higher revenue and earnings than NRx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A
NRx Pharmaceuticals	$2.29M	59.25	-$28.62M	-$1.09	N/A

Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for NRx Pharmaceuticals and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat NRx Pharmaceuticals' score of 1.08 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
NRx Pharmaceuticals	Positive

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NRx Pharmaceuticals beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Apollomics compare to Milestone Pharmaceuticals?

Apollomics (NASDAQ:APLM) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Apollomics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 525.00%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.87 equaled Milestone Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Apollomics	Very Positive
Milestone Pharmaceuticals	Very Positive

Apollomics has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Apollomics has higher revenue and earnings than Milestone Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.80	-$10.94M	N/A	N/A
Milestone Pharmaceuticals	$1.78M	80.95	-$63.06M	-$0.68	N/A

Summary

Milestone Pharmaceuticals beats Apollomics on 7 of the 12 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.99M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	N/A	21.48	27.14	23.64
Price / Sales	4.80	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-6.43	7.88	10.28	6.07
Net Income	-$10.94M	$23.86M	$3.60B	$331.99M
7 Day Performance	0.35%	-3.82%	-1.27%	-0.63%
1 Month Performance	-15.52%	-2.61%	-0.37%	-2.00%
1 Year Performance	198.31%	32.79%	18.30%	13.62%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	0.8238 of 5 stars	$18.59 -1.5%	N/A	+202.2%	$39.99M	$8.50M	N/A	45	Positive News Gap Down
ACB Aurora Cannabis	0.8197 of 5 stars	$2.67 +0.2%	N/A	-44.5%	$163.47M	$247.82M	N/A	1,028	News Coverage
ORMP Oramed Pharmaceuticals	3.008 of 5 stars	$3.98 -0.5%	N/A	+79.9%	$162.90M	$2M	1.54	10	Positive News
MOLN Molecular Partners	2.6485 of 5 stars	$3.96 -1.1%	$8.38 +111.8%	+1.1%	$159.99M	$5.65M	N/A	180
NRXP NRx Pharmaceuticals	2.6577 of 5 stars	$4.37 +0.9%	$38.25 +775.3%	+25.4%	$158.33M	$1.23M	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. ACB, ORMP, MOLN, NRXP, and MIST

How does Apollomics compare to Aurora Cannabis?

Summary

How does Apollomics compare to Oramed Pharmaceuticals?

Summary

How does Apollomics compare to Molecular Partners?

Summary

How does Apollomics compare to NRx Pharmaceuticals?

Summary

How does Apollomics compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. ACB, ORMP, MOLN, NRXP, and MIST

How does Apollomics compare to Aurora Cannabis?

Is ACB or APLM more profitable?

Which has more risk & volatility, ACB or APLM?

Do institutionals and insiders have more ownership in ACB or APLM?

Do analysts rate ACB or APLM?

Which has stronger earnings and valuation, ACB or APLM?

Does the media favor ACB or APLM?

Summary

How does Apollomics compare to Oramed Pharmaceuticals?

Does the media refer more to APLM or ORMP?

Which has more risk and volatility, APLM or ORMP?

Do insiders & institutionals have more ownership in APLM or ORMP?

Do analysts recommend APLM or ORMP?

Is APLM or ORMP more profitable?

Which has preferable valuation & earnings, APLM or ORMP?

Summary

How does Apollomics compare to Molecular Partners?

Is APLM or MOLN more profitable?

Do institutionals and insiders believe in APLM or MOLN?

Do analysts rate APLM or MOLN?

Does the media prefer APLM or MOLN?

Which has preferable earnings and valuation, APLM or MOLN?

Which has more volatility and risk, APLM or MOLN?

Summary

How does Apollomics compare to NRx Pharmaceuticals?

Do analysts prefer APLM or NRXP?

Is APLM or NRXP more profitable?

Which has better earnings & valuation, APLM or NRXP?

Which has more risk & volatility, APLM or NRXP?

Does the media prefer APLM or NRXP?

Do institutionals & insiders believe in APLM or NRXP?

Summary

How does Apollomics compare to Milestone Pharmaceuticals?

Is APLM or MIST more profitable?

Do analysts recommend APLM or MIST?

Does the media prefer APLM or MIST?

Which has more risk and volatility, APLM or MIST?

Do insiders & institutionals believe in APLM or MIST?

Which has higher earnings & valuation, APLM or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools